ClinicalTrials.gg
RecruitingNCT07083323Updated Nov 25, 2025

A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors

A Phase 1/2 interventional study of HY05350 for injection and HY05350 for injection in Advanced Solid Tumor, sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
262
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced solid tumors.

Read the detailed description

This study is a multicenter, open-label phase I/II clinical trial divided into two parts: dose escalation part (Part 1) and dose expansion part (Part 2). The main objectives of the first part are to evaluate the safety and tolerability of HY05350 for injection as monotherapy in patients with mesothelin-positive advanced solid tumors, and to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase 2 Dose (RP2D) or the recommended dose for subsequent clinical studies. The main objective of the second part is to evaluate the anti-tumor efficacy of HY05350 for injection. The study includes patients with cytologically or pathologically confirmed advanced solid tumors who have failed standard treatment.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Sichuan Huiyu Pharmaceutical Co., Ltd is the lead sponsor of 16 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years and ≤75 years at the time of signing the form, regardless of gender.
  2. Investigator-assessed expected survival period ≥3 months.
  3. (ECOG) performance status score of 0 to 1.
  4. Patients with or pathologically confirmed advanced solid tumors who have failed standard treatment.
  5. Subjects enrolled in the dose escalation stage must have evaluable tumor lesions, and subjects enrolled in the dose expansion stage must have at least one measurable tumor lesion (based on 1.1).
  6. Participant must have adequate main organ function.
  7. Agree to provide archived pathological tissues or fresh tumor tissues for detection of related markers such as MSLN and Programmed cell death ligand 1 () expression levels, and MSLN expression is positive.
  8. Female subjects of must have a negative serum pregnancy test within 7 days before the first drug administration, and be willing to use effective methods to prevent pregnancy and have no plans to donate eggs during the study period and for 6 months after the last drug administration. Male subjects must agree to have no plans to donate sperm and use effective contraceptive methods during the study period and for 6 months after the last drug administration. women must have been amenorrheic for at least 12 months to be considered non-childbearing.

Exclusion criteria

Exclusion Criteria:

  1. Received radiotherapy, chemotherapy, endocrine therapy, biological therapy, immunotherapy and other anti-tumor therapies within 4 weeks before the first drug administration.
  2. Received other drugs or participated in interventional medical device studies within 4 weeks before the first drug administration.
  3. Had received or planned to receive live/attenuated vaccines or mRNA vaccines within 4 weeks before screening.
  4. Pregnant or lactating women.
  5. Subjects with adverse events caused by previous anti-tumor therapy that remained > Grade 1 (based on 5.0) before the first drug administration.
  6. Subjects with a history of ≥ Grade 3 immune-related adverse events or who discontinued immunotherapy due to irAE of any grade.
  7. Subjects with primary central nervous system (CNS) tumors, symptomatic , meningeal , or a history of epilepsy are excluded.
  8. Subjects who underwent major surgery on vital organs (excluding ) within 4 weeks before the first drug administration, experienced significant trauma, or require major elective surgery during the trial.
  9. Subjects with a history of tissue or organ transplantation.
  10. Subjects who had severe infections within 4 weeks before the first drug administration.
  11. Positive test.
  12. Active , untreated chronic hepatitis B, or chronic hepatitis B that is treated but uncontrolled.
  13. Subjects with active virus(HCV) infection;
  14. Positive treponema pallidum antibody and confirmed positive by diagnostic test;
  15. Subjects with untreated or ongoing tuberculosis.
  16. Known severe allergic history, or known allergic reactions to macromolecular protein preparations/antibodies or any component of the investigational drug.
  17. History of active diseases or a history of autoimmune diseases with potential for recurrence.
  18. Subjects who received systemic or other within 14 days before the first drug administration.
  19. History of non-infectious pneumonia requiring glucocorticoid treatment or current interstitial lung disease.
  20. History of severe cardiovascular and cerebrovascular diseases.
  21. Subjects with thrombosis or bleeding risk.
  22. Known history of psychoactive substance abuse or drug use that is considered to affect study compliance.
  23. Except for the tumor enrolled in the study, subjects with other active malignant tumors within 1 year before the first drug administration.
  24. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage.
  25. Subjects deemed unsuitable for participation by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
262 participants (estimated)

Study arms

  • Experimental
    Part 1, the single-agent dose escalation of HY05350 for injection.

    Drug: HY05350 for injection

  • Experimental
    Part 2, dose expansion. The recommended dose will be established from the Dose Escalation part.

    Drug: HY05350 for injection

Interventions

  • DrugHY05350 for injection

    HY05350 should be administered intravenously at planned dosage, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.

  • DrugHY05350 for injection

    HY05350 should be administered intravenously at recommended dose, once a week, once every two weeks, or once every three weeks, until disease progression or intolerable toxicity occurs.

06

What researchers measure

Primary outcomes

  1. Part 1, the occurrence of dose limiting toxicity (DLT)

    Measure Description: DLT will be defined using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 or American Society for Transplantation and Cellular Therapy (ASTCT) criteria for Cytokine Release Syndrome (CRS).

    Time frame: At the end of Cycle 1 (each cycle is 28 days).

  2. Part 1, Incidence of Treatment-Emergent Adverse Events (TEAE)

    Measure Description: Incidence and severity of TEAE according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: Up to 2 years.

  3. Part 2, Objective Response Rate (ORR)

    Measure Description: The proportion of participants who have a Complete Response (CR) or a Partial Response (PR) based on Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1.

    Time frame: Up to 2 years.

Secondary outcomes

  1. Part 1, Peak Plasma Concentration (Cmax)

    Measure Description: Maximum concentration observed from the pharmacokinetic profile

    Time frame: At the end of Cycle 3 (each cycle is 28 days).

  2. Part 1, Area under the plasma concentration versus time curve (AUC)

    Measure Description: Area under the concentration versus time curve calculated using the trapezoidal method.

    Time frame: At the end of Cycle 3 (each cycle is 28 days).

  3. Part 1, Assessment of Anti-drug Antibody (ADA)

    Measure Description: Incidence, duration, titer of serum anti-HY05350 antibody (ADA)

    Time frame: Up to 2 years.

  4. Part 1, Objective Response Rate (ORR)

    Measure Description: Proportion of participants who have a complete response (CR) or a partial response (PR) determined by Investigator per the Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1.

    Time frame: Up to 2 years.

  5. Part 2, Duration Of Response (DOR)

    Measure Description: Duration Of Response (DOR) is defined as the time from the measurement criteria are first met for complete response (CR) /partial response (PR) (whichever is first recorded) until the first date that recurrent or progressive disease.

    Time frame: Up to 2 years.

  6. Part 2, Incidence of Treatment-Emergent Adverse Events (TEAE)

    Measure Description: Incidence and severity of TEAE according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: Up to 2 years.

  7. Part 2, Peak Plasma Concentration (Cmax)

    Measure Description: Maximum concentration observed from the pharmacokinetic profile.

    Time frame: At the end of Cycle 3 (each cycle is 28 days).

  8. Part 2, Assessment of Anti-drug Antibody (ADA)

    Measure Description: Incidence, duration, titer of serum anti-HY05350 antibody (ADA).

    Time frame: Up to 2 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Mar 2028, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2025
First posted
Jul 24, 2025
StartActual
Jul 22, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07083323
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Jul 22, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Nov 25, 2025

Study contacts

Chun Wan
Contact
chun.wan3717@huiyupharma.com
028-86021875
Lin Shen
Contact
Chun Wan
study director · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion